Increased susceptibility to amyloid-β-induced neurotoxicity in mice lacking the low-density lipoprotein receptor

Journal of Alzheimer's Disease

Volumn 41, Issue 1, 2014, Pages 43-60

  De Oliveira, Jade ^a   Moreira, Eduardo Luiz Gasnhar ^a   Dos Santos, Danúbia Bonfanti ^a   Piermartiri, Tetsadê Camboim ^a   Dutra, Rafael Cypriano ^a   Pinton, Simone ^b   Tasca, Carla Inês ^a   Farina, Marcelo ^a   Prediger, Rui Daniel Schröder ^a   De Bem, Andreza Fabro ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSIDADE FEDERAL DO PAMPA   (Brazil)

Author keywords

Alzheimer's disease; amyloid peptide; hypercholesterolemia; LDL receptor; learning and memory; oxidative stress

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[1-40]; GLUTATHIONE; LOW DENSITY LIPOPROTEIN RECEPTOR; SUPEROXIDE DISMUTASE; AMYLOID BETA PROTEIN; ANTIOXIDANT; PEPTIDE FRAGMENT;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; HIPPOCAMPUS; MEMORY DISORDER; MOLECULAR MECHANICS; MOUSE; NERVE CELL MEMBRANE; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REFERENCE MEMORY; SPATIAL LEARNING; SYNAPTIC TRANSMISSION; AMYLOIDOSIS; ANIMAL; ASTROCYTE; C57BL MOUSE; CAPILLARY PERMEABILITY; COMPLICATION; DISEASE MODEL; GENETICS; GLIOSIS; IMMUNOMODULATION; KNOCKOUT MOUSE; MEMORY DISORDERS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREFRONTAL CORTEX; SHORT TERM MEMORY; SPATIAL MEMORY;

ACETYLCHOLINESTERASE; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; ANIMALS; ANTIOXIDANTS; ASTROCYTES; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CELL MEMBRANE PERMEABILITY; DISEASE MODELS, ANIMAL; GLIOSIS; HIPPOCAMPUS; MEMORY DISORDERS; MEMORY, SHORT-TERM; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROIMMUNOMODULATION; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PREFRONTAL CORTEX; RECEPTORS, LDL; SPATIAL MEMORY; SUPEROXIDE DISMUTASE;

EID: 84902278355     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132228     Document Type: Article

References (90)

1. Goedert M, Spillantini MG (2006) A century of Alzheimer's disease. Science 314, 777-781.
2. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3, 75-80.
3. Mesulam M (2004) The cholinergic lesion of Alzheimer's disease: Pivotal factor or side show? Learn Mem 11, 43-49.
4. Mesulam M (2012) Cholinergic aspects of aging and Alzheimer's disease. Biol Psychiatry 71, 760-761.
5. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315, 1241-1245.
6. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimer's disease: Clinical trials and drug development. Lancet Neurol 9, 702-716.
7. Hardy JA, Higgins GA (1992) Alzheimer's disease: The amyloid cascade hypothesis. Science 256, 184-185.
8. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
9. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
10. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
11. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE (1998) Cerebral amyloid angiopathy: Amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 153, 725-733.
12. Chow VW, Mattson MP, Wong PC, Gleichmann M (2010) An overview of APP processing enzymes and products. Neuro-molecular Med 12, 1-12.
13. Kurz A, Perneczky R (2011) Amyloid clearanceasa treatment target against Alzheimer's disease. J Alzheimers Dis24 (Suppl 2), 61-73.
14. Mandrekar-Colucci S, Landreth GE (2010) Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets 9, 156-167.
15. Wilcox KC, Lacor PN, Pitt J, Klein WL (2011) Abeta oligomer-induced synapse degeneration in Alzheimer's disease. Cell Mol Neurobiol 31, 939-948.
16. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421.
17. Ferreira ST, Klein WL (2011) The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem 96, 529-543.
18. Ricciarelli R, Canepa E, Marengo B, Marinari UM, Poli G, Pronzato MA, Domenicotti C (2012) Cholesterol and Alzheimer's disease: A still poorly understood correlation. IUBMB Life 64, 931-935.
19. Bodovitz S, Klein WL (1996) Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 271, 4436-4440.
20. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95, 6460-6464.
21. Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160, 113-123.
22. Vetrivel KS, Thinakaran G (2010) Membrane rafts in Alzheimer's disease beta-amyloid production. Biochim Bio-phys Acta 1801, 860-867.
23. Xiong H, Callaghan D, Jones A, Walker DG, Lue LF, Beach TG, Sue LI, Woulfe J, Xu H, Stanimirovic DB, Zhang W (2008) Cholesterol retention in Alzheimer's brain is responsible for high beta-and gamma-secretase activities and Abeta production. Neurobiol Dis 29, 422-437.
24. Morell P, Jurevics H (1996) Origin of cholesterol in myelin. Neurochem Res 21, 463-470.
25. Pfrieger FW, Ungerer N (2011) Cholesterol metabolism in neurons and astrocytes. Prog Lipid Res 50, 357-371.
26. Herz J, Bock HH (2002) Lipoprotein receptors in the nervous system. Annu Rev Biochem 71, 405-434.
27. Herz J (2001) Deconstructing the LDL receptor-a rhapsody in pieces. Nat Struct Biol 8, 476-478.
28. Harris-White ME, Frautschy SA (2005) Low density lipopro-tein receptor-related proteins (LRPs), Alzheimer's and cognition. Curr Drug Targets CNS Neurol Disord 4, 469-480.
29. Hobbs HH, Brown MS, Goldstein JL (1992) Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1, 445-466.
30. Soutar AK, Naoumova RP (2007) Mechanisms of disease: Genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 4, 214-225.
31. Zambon D, Quintana M, Mata P, Alonso R, Benavent J, Cruz-Sanchez F, Gich J, Pocovi M, Civeira F, Capurro S, Bachman D, Sambamurti K, Nicholas J, Pappolla MA (2010) Higher incidence of mild cognitive impairment in familial hyperc-holesterolemia. Am J Med 123, 267-274.
32. Mariani E, Monastero R, Mecocci P (2007) Mild cognitive impairment: A systematic review. J Alzheimers Dis 12, 23-35.
33. Mulder M, Jansen PJ, Janssen BJ, van de Berg WD, van der Boom H, Havekes LM, deKloet RE, Ramaekers FC, Blokland A (2004) Low-density lipoprotein receptor-knockout mice display impaired spatial memory associated with a decreased synaptic density in the hippocampus. Neurobiol Dis 16, 212-219.
34. de Oliveira J, Hort MA, Moreira EL, Glaser V, Ribeiro-do-Valle RM, Prediger RD, Farina M, Latini A, de Bem AF (2011) Positive correlation between elevated plasma cholesterol levels and cognitive impairments in LDL receptor knockout mice: Relevance of cortico-cerebral mitochondrial dysfunction and oxidative stress. Neuroscience 197, 99-106.
35. -/-): Evidence of antioxidant imbalance and increased acetylcholinesterase activity in the prefrontal cortex. J Alzheimers Dis 32, 495-511.
36. Moreira EL, Aguiar AS Jr, de Carvalho CR, Santos DB, de Oliveira J, de Bem AF, Xikota JC, Walz R, Farina M, Predi-ger RD (2013) Effects of lifestyle modifications on cognitive impairments in a mouse model of hypercholesterolemia. Neu-rosci Lett 541, 193-198.
37. Cao D, Fukuchi K, Wan H, Kim H, Li L (2006) Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging 27, 1632-1643.
38. Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM (2009) Over-expression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 64, 632-644.
39. Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM (2012) Low-density lipoprotein receptor represents an apolipopro-tein E-independent pathway of Abeta uptake and degradation by astrocytes. J Biol Chem 287, 13959-13971.
40. Prediger RD, Franco JL, Pandolfo P, Medeiros R, Duarte FS, Di Giunta G, Figueiredo CP, Farina M, Calixto JB, Takahashi RN, Dafre AL (2007) Differential susceptibility following beta-amyloid peptide-(1-40) administration in C57BL/6 and Swiss albino mice: Evidence foradissociation between cognitive deficits and the glutathione system response. Behav Brain Res 177, 205-213.
41. Piermartiri TC, Figueiredo CP, Rial D, Duarte FS, Bezerra SC, Mancini G, de Bem AF, Prediger RD, Tasca CI (2010) Ator-vastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-beta (1-40) administration in mice: Evidence for dissociation between cognitive deficits and neuronal damage. Exp Neurol 226, 274-284.
42. Figueiredo CP, Bicca MA, Latini A, Prediger RD, Medeiros R, Calixto JB (2011) Folic acid plus alpha-tocopherol mitigates amyloid-beta-induced neurotoxicity through modulation of mitochondrial complexes activity. J Alzheimers Dis 24, 61-75.
43. Santos DB, Peres KC, Ribeiro RP, Colle D, dos Santos AA, Moreira EL, Souza DO, Figueiredo CP, Farina M (2012) Probucol, a lipid-lowering drug, prevents cognitive and hip-pocampal synaptic impairments induced by amyloid beta peptide in mice. Exp Neurol 233, 767-775.
44. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD (1996) Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 382, 716-719.
45. Prediger RD, Medeiros R, Pandolfo P, Duarte FS, Passos GF, Pesquero JB, Campos MM, Calixto JB, Takahashi RN (2008) Genetic deletion or antagonism of kinin B (1) and B (2) receptors improves cognitive deficits in a mouse model of Alzheimer's disease. Neuroscience 151, 631-643.
46. Murai T, Okuda S, Tanaka T, Ohta H (2007) Characteristics of object location memory in mice: Behavioral and pharmacological studies. Physiol Behav 90, 116-124.
47. Assini FL, Duzzioni M, Takahashi RN (2009) Object location memory in mice: Pharmacological validation and further evidence of hippocampal CA1 participation. Behav Brain Res 204, 206-211.
48. Spowart-Manning L, van der Staay FJ (2004) The T-maze continuous alternation task for assessing the effects ofputative cognition enhancers in the mouse. Behav Brain Res 151, 37-46.
49. Rodgers RJ, Howard K, Stewart S, Waring P, Wright FL (2010) Anxioselective profile of glycineB receptor partial agonist, D-cycloserine, inplus-maze-naive but not plus-maze-experienced mice. Eur J Pharmacol 646, 31-37.
50. Rodgers RJ, Johnson NJ, Cole JC, Dewar CV, Kidd GR, Kimpson PH (1996) Plus-maze retest profile in mice: Importance of initial stages of trail 1 and response to post-trail cholinergic receptor blockade. Pharmacol Biochem Behav 54, 41-50.
51. Poleszak E, Socala K, Szopa A, Wrobel A, Szewczyk B, Kasperek R, Blicharska E, Nowak G, Wlaz P (2011) Involve-mentofNMDA receptor complexinthe anxiolytic-like effects of chlordiazepoxide in mice. J Neural Transm 118, 857-864.
52. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetyl-cholinesterase activity. Biochem Pharmacol 7, 88-95.
53. Hissin PJ, Hilf R (1976) A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74, 214-226.
54. Carlberg I, Mannervik B (1985) Glutathione reductase. Methods Enzymol 113, 484-490.
55. Wendel A (1981) Glutathione peroxidase. Methods Enzymol 77, 325-333.
56. Misra HP, Fridovich I (1972) The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247, 3170-3175.
57. Hempel SL, Buettner GR, O'Malley YQ, Wessels DA, Flaherty DM (1999) Dihydrofluorescein diacetate is superior for detecting intracellular oxidants: Comparison with 2', 7'-dichlorodihydrofluorescein diacetate, 5 (and 6)-carboxy-2', 7'-dichlorodihydrofluorescein diacetate, and dihydrorho-damine 123. Free Radic Biol Med 27, 146-159.
58. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193, 265-275.
59. Moreira EL, de Oliveira J, Dutra MF, Santos DB, Goncalves CA, Goldfeder EM, de Bem AF, Prediger RD, Aschner M, Farina M (2012) Does methylmercury- induced hypercholesterolemia play a causal role in its neurotoxicity and cardiovascular disease? Toxicol Sci 130, 373-382.
60. Deiana S, Platt B, Riedel G (2011) The cholinergic system and spatial learning. Behav Brain Res 221, 389-411.
61. Soreq H, Seidman S (2001) Acetylcholinesterase-new roles for an old actor. Nat Rev Neurosci 2, 294-302.
62. Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain. Biol Chem 384, 505-516.
63. Lovell MA, Ehmann WD, Butler SM, Markesbery WR (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45, 1594-1601.
64. Vehmas AK, Kawas CH, Stewart WF, Troncoso JC (2003) Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging 24, 321-331.
65. Nagelhus EA, Mathiisen TM, Ottersen OP (2004) Aquaporin-4 in the central nervous system: Cellular and subcellular distribution and coexpression with KIR4. 1. Neuroscience 129, 905-913.
66. Tomas-Camardiel M, Venero JL, Herrera AJ, De Pablos RM, Pintor-Toro JA, Machado A, Cano J (2005) Blood-brain barrier disruption highly induces aquaporin-4 mRNA and protein in perivascular and parenchymal astrocytes: Protective effect by estradiol treatment in ovariectomized animals. J Neurosci Res 80, 235-246.
67. Medeiros R, Kitazawa M, Chabrier MA, Cheng D, Baglietto-Vargas D, Kling A, Moeller A, Green KN, LaFerla FM (2012) Calpain inhibitor A-705253 mitigates Alzheimer's diseaselike pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol 181, 616-625.
68. Mulder M, Koopmans G, Wassink G, Al Mansouri G, Simard ML, Havekes LM, Prickaerts J, Blokland A (2007) LDL receptor deficiency results in decreased cell proliferation and presynaptic bouton density in the murine hippocampus. Neurosci Res 59, 251-256.
69. dos Santos VV, Santos DB, Lach G, Rodrigues AL, Farina M, De Lima TC, Prediger RD (2013) Neuropeptide Y (NPY) prevents depressive-like behavior, spatial memory deficits and oxidative stress following amyloid-beta (Abeta (1-40)) administration in mice. Behav Brain Res 244, 107-115.
70. Rapp JH, Pan XM, Neumann M, Hong M, Hollenbeck K, Liu J (2008) Microemboli composed of cholesterol crystals disrupt the blood-brain barrier and reduce cognition. Stroke 39, 2354-2361.
71. Nicchia GP, Nico B, Camassa LM, Mola MG, Loh N, Der-mietzel R, Spray DC, Svelto M, Frigeri A (2004) The role of aquaporin-4 in the blood-brain barrier development and integrity: Studies in animal and cell culture models. Neuro-science 129, 935-945.
72. Deane R, Wu Z, Zlokovic BV (2004) RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35, 2628-2631.
73. Zlokovic BV (2004) Clearing amyloid through the blood-brain barrier. J Neurochem 89, 807-811.
74. Jaya Prasanthi RP, Schommer E, Thomasson S, Thompson A, Feist G, Ghribi O (2008) Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease. Mech Ageing Dev 129, 649-655.
75. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2, a006346.
76. Sofroniew MV, Vinters HV (2010) Astrocytes: Biology and pathology. Acta Neuropathol 119, 7-35.
77. Le TM, Jiang H, Cunningham GR, Magarik JA, Barge WS, Cato MC, Farina M, Rocha JB, Milatovic D, Lee E, Aschner M, Summar ML (2011) gamma-Glutamylcysteine ameliorates oxidative injury in neurons and astrocytes in vitro and increases brain glutathione in vivo. Neurotoxicology 32, 518-525.
78. Lewerenz J, Maher P (2011) Control of redox state and redox signaling by neural antioxidant systems. Antioxid Redox Signal 14, 1449-1465.
79. Oliveira HC, Cosso RG, Alberici LC, Maciel EN, Salerno AG, Dorighello GG, Velho JA, de Faria EC, Vercesi AE (2005) Oxidative stress in atherosclerosis-prone mouse is due to low antioxidant capacity of mitochondria. FASEB J 19, 278-280.
80. Arumugam TV, Gleichmann M, Tang SC, Mattson MP (2006) Hormesis/preconditioning mechanisms, the nervous system and aging. Ageing Res Rev 5, 165-178.
81. Joshi G, Johnson JA (2012) The Nrf2-ARE pathway: A valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov 7, 218-229.
82. Uttara B, Singh AV, Zamboni P, Mahajan RT (2009) Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options. Curr Neu-ropharmacol 7, 65-74.
83. LeBel CP, Bondy SC (1991) Oxygen radicals: Common mediators of neurotoxicity. Neurotoxicol Teratol 13, 341-346.
84. Khadrawy YA, Nour NA, Aboul Ezz HS (2011) Effect of oxidative stress induced by paradoxical sleep deprivation on the activities of Na+, K+-ATPase and acetylcholinesterase in the cortex and hippocampus of rat. Transl Res 157, 100-107.
85. Moreira EL, de Oliveira J, Engel DF, Walz R, de Bem AF, Farina M, Prediger RD (2013) Hypercholesterolemia induces short-term spatial memory impairments in mice: Up-regulation of acetylcholinesterase activity as an early and causal event? J Neural Transm, doi: 10.1007/s00702-013-1107-9
86. Moran MA, Mufson EJ, Gomez-Ramos P (1993) Colocaliza-tion of cholinesterases with beta amyloid protein in aged and Alzheimer's brains. Acta Neuropathol 85, 362-369.
87. Sberna G, Saez-Valero J, Beyreuther K, Masters CL, Small DH (1997) The amyloid beta-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. J Neurochem 69, 1177-1184.
88. Lafon-Cazal M, Pietri S, Culcasi M, Bockaert J (1993) NMDA-dependent superoxide production and neurotoxicity. Nature 364, 535-537.
89. Yan Z, Feng J (2004) Alzheimer's disease: Interactions between cholinergic functions and beta-amyloid. Curr Alzheimer Res 1, 241-248.
90. Takeda S, Sato N, Niisato K, Takeuchi D, Kurinami H, Shi-nohara M, Rakugi H, Kano M, Morishita R (2009) Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease. Brain Res 1280, 137-147.